Ticagrelor in Patients with Stable Coronary Disease and Diabetes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear. METHODS: In this randomized, double-blind trial, we assigned patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus to receive either ticagrelor plus aspirin or placebo plus aspirin. Patients with previous myocardial infarction or stroke were excluded. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major bleeding as defined by the Thrombolysis in Myocardial Infarction (TIMI) criteria. RESULTS: A total of 19,220 patients underwent randomization. The median follow-up was 39.9 months. Permanent treatment discontinuation was more frequent with ticagrelor than placebo (34.5% vs. 25.4%). The incidence of ischemic cardiovascular events (the primary efficacy outcome) was lower in the ticagrelor group than in the placebo group (7.7% vs. 8.5%; hazard ratio, 0.90; 95% confidence interval [CI], 0.81 to 0.99; P = 0.04), whereas the incidence of TIMI major bleeding was higher (2.2% vs. 1.0%; hazard ratio, 2.32; 95% CI, 1.82 to 2.94; P<0.001), as was the incidence of intracranial hemorrhage (0.7% vs. 0.5%; hazard ratio, 1.71; 95% CI, 1.18 to 2.48; P = 0.005). There was no significant difference in the incidence of fatal bleeding (0.2% vs. 0.1%; hazard ratio, 1.90; 95% CI, 0.87 to 4.15; P = 0.11). The incidence of an exploratory composite outcome of irreversible harm (death from any cause, myocardial infarction, stroke, fatal bleeding, or intracranial hemorrhage) was similar in the ticagrelor group and the placebo group (10.1% vs. 10.8%; hazard ratio, 0.93; 95% CI, 0.86 to 1.02). CONCLUSIONS: In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin. (Funded by AstraZeneca; THEMIS ClinicalTrials.gov number, NCT01991795.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (201,202).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“However, a higher incidence of major bleeding, including intracranial hemorrhage, was noted with dual antiplatelet therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (189,190).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [189]
In the citing paper
“Thus, an unfavourable benefit-risk profile is associated with adding ticagrelor to ASA in this setting.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
In the citing paper
“Over a median 3.3 years of follow-up, the primary efficacy outcome of CV death, MI, or stroke showed a marginal 10% RR reduction by ticagrelor vs. placebo, while both Thrombolysis in Myocardial Infarction (TIMI) major and intracranial bleeding were significantly increased.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Self-citationLong-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Self-citationTwelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Self-citationBhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.025 · Cited by 805
Self-citationVranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
Self-citation
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Rivaroxaban in Peripheral Artery Disease after Revascularization
Bonaca, M. P., Bauersachs, R. M., Anand, S. S., Debus, E. S., Nehler, M. R., Patel, M. R., Fanelli, F., Capell, W. H., Diao, L., Jaeger, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2000052 · Cited by 1,045
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Self-citation2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Targeting cardiovascular inflammation: next steps in clinical translation
Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa099 · Cited by 443
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
Nakamura, M., Kimura, K., Kimura, T., Ishihara, M., Otsuka, F., Kozuma, K., Kosuge, M., Shinke, T., Nakagawa, Y., Natsuaki, M., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1109 · Cited by 352
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Self-citationAngiolillo, D. J., Bhatt, D. L., Cannon, C. P., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Granger, C. B., Holmes, D. R., Lopes, R. D., Mehran, R., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050438 · Cited by 302
Self-citationAntiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies
Xenogiannis, I., Zenati, M., Bhatt, D. L., Rao, S. V., Rodés-Cabau, J., Goldman, S., Shunk, K. A., Mavromatis, K., Banerjee, S., Alaswad, K., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052163 · Cited by 211
Self-citationBhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31887-2 · Cited by 209
Self-citationThe Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
Khan, S. U., Singh, M., Valavoor, S., Khan, M. U., Lone, A. N., Khan, M. Z., Khan, M. S., Mani, P., Kapadia, S. R., Michos, E. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046308 · Cited by 183
Self-citationLordan, R., Tsoupras, A., & Zabetakis, I. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100694 · Cited by 179
Capodanno, D., Mehran, R., Krucoff, M. W., Baber, U., Bhatt, D. L., Capranzano, P., Collet, J.-P., Cuisset, T., De Luca, G., De Luca, L., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064473 · Cited by 179
Self-citationChiarito, M., Sanz-Sánchez, J., Cannata, F., Cao, D., Sturla, M., Panico, C., Godino, C., Regazzoli, D., Reimers, B., De Caterina, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30315-9 · Cited by 174
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 161
Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046448 · Cited by 158
Self-citation2024 Clinical practice guidelines for Stable coronary artery disease
Барбараш, О. Л., Karpov, Y. A., Panov, A. V., Akchurin, R. S., Alekyan, B. G., Alekhin, M. N., Aronov, D. M., HARUTYUNYAN, G., Belenkov, Y. N., Boytsov, S. A., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6110 · Cited by 182
Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., Knutsson, M., Ladenvall, P., Molina, C. A., Wang, Y., Johnston, S. C., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.032239 · Cited by 102
Cao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 104
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
Patrono, C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae324 · Cited by 120
Antiplatelet therapy in cardiovascular disease: Current status and future directions
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15221 · Cited by 117
Chen, H., Tran, D., Yang, H., Nylander, S., Birnbaum, Y., & Ye, Y. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06978-y · Cited by 105
Sandner, S. E., Redfors, B., Angiolillo, D. J., Audisio, K., Fremes, S. E., Janssen, P. W. A., Kulik, A., Mehran, R., Peper, J., Ruel, M., et al. (2022) · JAMA · doi:10.1001/jama.2022.11966 · Cited by 98
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationKwok, C. S., Wong, C. W., Kontopantelis, E., Barac, A., Brown, S.-A. N., Velagapudi, P., Hilliard, A. A., Bharadwaj, A. S., Alraies, M. C., Mohamed, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1032 · Cited by 88
Self-citationPrimary and Secondary Outcome Reporting in Randomized Trials
Pocock, S. J., Rossello, X., Owen, R., Collier, T. J., Stone, G. W., & Rockhold, F. W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.024 · Cited by 78
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
Capodanno, D., Baber, U., Bhatt, D. L., Collet, J., Dangas, G., Franchi, F., Gibson, C. M., Gwon, H., Kastrati, A., Kimura, T., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00725-6 · Cited by 76
Self-citationIntracranial Hemorrhage During Dual Antiplatelet Therapy
Ha, A. C. T., Bhatt, D. L., Rutka, J. T., Johnston, S. C., Mazer, C. D., & Verma, S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.048 · Cited by 81
Self-citationNusca, A., Viscusi, M. M., Piccirillo, F., Filippis, A. D., Nenna, A., Spadaccio, C., Nappi, F., Chello, C., Mangiacapra, F., Grigioni, F., et al. (2022) · Life · doi:10.3390/life12030393 · Cited by 76
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease
Valgimigli, M., Aboyans, V., Angiolillo, D. J., Atar, D., Capodanno, D., Halvorsen, S., James, S. K., Jüni, P., Kunadian, V., Landi, A., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad032 · Cited by 67
Self-citationHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Self-citationBainey, K. R., Welsh, R. C., Connolly, S. J., Marsden, T., Bosch, J., Fox, K. A. A., Steg, P. G., Vinereanu, D., Connolly, D. L., Berkowitz, S. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044598 · Cited by 62
Self-citationAntithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 74
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery
Bhatt, D. L., Pollack, C. V., Mazer, C. D., Angiolillo, D. J., Steg, P. G., James, S. K., Weitz, J. I., Ramnath, R., Arnold, S. E., Mays, M. C., et al. (2021) · NEJM Evidence · doi:10.1056/evidoa2100047 · Cited by 67
Self-citationLi, W., Zhu, W., Wang, A., Zhang, G., Zhang, Y., Wang, K., Zhang, Y., Wang, C., Zhang, L., Zhao, H., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.032989 · Cited by 63
Capodanno, D., & Angiolillo, D. J. (2020) · Circulation · doi:10.1161/circulationaha.120.045465 · Cited by 65
Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines
Mas-Lladó, C., González‐Del‐Hoyo, M., Siquier-Padilla, J., Peña, L. B., Coughlan, J. J., de la Villa, B. G., Peral, V., & Rosselló, X. (2023) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcad007 · Cited by 64
Antithrombotic Management of Elderly Patients With Coronary Artery Disease
Capranzano, P., & Angiolillo, D. J. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.01.040 · Cited by 60
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 59
Personalised antiplatelet therapies for coronary artery disease: what the future holds
Capodanno, D., & Angiolillo, D. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad362 · Cited by 58
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 56
Self-citationGalli, M., Ortega‐Paz, L., Franchi, F., Rollini, F., & Angiolillo, D. J. (2022) · Pharmacogenomics · doi:10.2217/pgs-2022-0057 · Cited by 54
Khan, H., Kanny, O., Syed, M. H., & Qadura, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911317 · Cited by 58
Galli, M., Franchi, F., Rollini, F., Cavallari, L. H., Capodanno, D., Crea, F., & Angiolillo, D. J. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1927709 · Cited by 52
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective
Mangieri, A., Gallo, F., Sticchi, A., Khokhar, A. A., Laricchia, A., Giannini, F., & Colombo, A. (2020) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-020-00642-w · Cited by 52
Dual Antiplatelet Therapy: A Concise Review for Clinicians
Virk, H. U. H., Escobar, J., Rodríguez, M., Bates, E., Khalid, U., Jneid, H. M., Birnbaum, Y., Levine, G. N., Smith, S. C., & Krittanawong, C. (2023) · Life · doi:10.3390/life13071580 · Cited by 63
Dual Antiplatelet Therapy in Coronary Artery Disease
Sharma, R., Kumar, P., Prashanth, S. P., & Belagali, Y. R. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00197-0 · Cited by 58
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective
Rocca, B., & Patrono, C. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108008 · Cited by 48
Carvalho, P. E. P., Gewehr, D. M., Nascimento, B. R., Melo, L., Burkhardt, G., Rivera, A., Braga, M. A. P., Guimarães, P. O., Mehran, R., Windecker, S., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3216 · Cited by 56
Self-citationPatient-tailored antithrombotic therapy following percutaneous coronary intervention
van der Sangen, N. M. R., Rozemeijer, R., Yin, D. R. P. P. C. P., Valgimigli, M., Windecker, S., James, S. K., Buccheri, S., ten Berg, J. M., Henriques, J. P. S., Voskuil, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1097 · Cited by 42
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus
Ndrepepa, G., Kastrati, A., Menichelli, M., Neumann, F., Wöhrle, J., Bernlochner, I., Richardt, G., Witzenbichler, B., Sibbing, D., Gewalt, S., et al. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.07.032 · Cited by 45
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 44
Mak, K.-H., Vidal-Petiot, E., Young, R., Sorbets, E., Greenlaw, N., Ford, I., Tendera, M., Ferrari, R., Tardif, J.-C., Udell, J. A., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab011 · Cited by 39
Self-citationTicagrelor: clinical development and future potential
Sanderson, N. C., Parker, W. A., & Storey, R. F. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202044 · Cited by 46
Furtado, R. H. M., Nicolau, J. C., Magnani, G., Im, K., Bhatt, D. L., Storey, R. F., Steg, P. G., Špinar, J., Budaj, A., Kontny, F. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz821 · Cited by 36
Self-citationKuno, T., Fujisaki, T., Shoji, S., Sahashi, Y., Tsugawa, Y., Iwagami, M., Takagi, H., Briasoulis, Α., Deharo, P., Cuisset, T., et al. (2022) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.122.011990 · Cited by 39
Self-citationNavarese, E. P., Landi, A., Oliva, A., Piccolo, R., Aboyans, V., Angiolillo, D. J., Atar, D., Capodanno, D., Fox, K. A. A., Halvorsen, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad016 · Cited by 38
Self-citationKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Bohula, E. A., Marston, N., Ruzza, A., Murphy, S. A., Ferrari, G. M. D., Díaz, R., Leiter, L. A., Elliott‐Davey, M., Wang, H., Bhatia, A. K., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.12.004 · Cited by 42
Self-citationWeissler, E. H., Jones, W. S., Désormais, I., Debus, S., Mazzolai, L., Espinola–Klein, C., Nikol, S., Nehler, M. R., Sillesen, H. H., Aboyans, V., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.001 · Cited by 35
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Self-citationManagement of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies
King, R. W., Canonico, M. E., Bonaca, M. P., & Hess, C. N. (2022) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2022.100513 · Cited by 36
Gao, C., Tomaniak, M., Takahashi, K., Kawashima, H., Wang, R., Hara, H., Ono, M., Montalescot, G., Garg, S., Haude, M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01153-x · Cited by 27
Self-citationCollet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 44
Self-citationPloumen, E. H., Pinxterhuis, T. H., Zocca, P., Roguin, A., Anthonio, R. L., Schotborgh, C. E., Benit, E., Aminian, A., Danse, P. W., Doggen, C. J. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01405-4 · Cited by 27
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54
Bonaca, M. P., Im, K., Magnani, G., Bansilal, S., Dellborg, M., Storey, R. F., Bhatt, D. L., Steg, P. G., Cohen, M. C., Johanson, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac402 · Cited by 30
Self-citationA disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
Pan, Y., Wang, Y., Zheng, Y., Chen, J., & Li, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1251961 · Cited by 33
Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W. J. C., Hamm, C. W., Steg, P. G., Heg, D., Branca, M., et al. (2020) · EuroIntervention · doi:10.4244/eij-d-20-00145 · Cited by 26
Self-citationHeeney, M. M., Abboud, M. R., Githanga, J. N., Inusa, B. P. D., Kanter, J., Michelson, A. D., Nduba, V., Musiime, V., Apte, M., Inati, A. C., et al. (2022) · Blood · doi:10.1182/blood.2021014095 · Cited by 29
Self-citationMangiacapra, F., Buono, M. G. D., Abbate, A., Gori, T., Barbato, E., Montone, R. A., Crea, F., & Niccoli, G. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.02.009 · Cited by 27
Gebrie, D., Manyazewal, T., Ejigu, D. A., & Makonnen, E. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s312997 · Cited by 28
Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease
Hess, C. N., & Bonaca, M. P. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.009584 · Cited by 27
Laborante, R., Borovac, J. A., Galli, M., Rodolico, D., Ciliberti, G., Restivo, A., Cappannoli, L., Arcudi, A., Vergallo, R., Zito, A., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1009475 · Cited by 28
Antithrombotic therapy for patients with chronic coronary syndromes
Parker, W. A., & Storey, R. F. (2020) · Heart · doi:10.1136/heartjnl-2020-316914 · Cited by 25
Giubilato, S., Lucà, F., Abrignani, M. G., Gatto, L., Rao, C. M., Ingianni, N., Amico, F., Rossini, R., Caretta, G., Cornara, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185989 · Cited by 33
Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
Fei, Y., Lam, C. K., & Cheung, B. M. Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-73871-x · Cited by 24
Krantz, M. J., Debus, S. E., Hsia, J. A., Patel, M. R., Anand, S. S., Nehler, M. R., Hess, C. N., Capell, W. H., Bracken, T., Szarek, M. J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab408 · Cited by 26
Siasos, G., Skotsimara, G., Oikonomou, E. K., Sagris, Μ., Mystakidi, V. C., Bletsa, E., Stampouloglou, P. K., Theofilis, P., Charalampous, G., & Tousoulis, D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200417145605 · Cited by 23
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 28
Roule, V., Alexandre, J., Lemaître, A., Chrétien, B., Sassier, M., Fédrizzi, S., Beygui, F., & Dolladille, C. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07459-8 · Cited by 23
Gebrie, D., Demsie, D. G., & Manyazewal, T. (2021) · Scientific Reports · doi:10.1038/s41598-020-80603-8 · Cited by 22
Leiter, L. A., Bhatt, D. L., McGuire, D. K., Teoh, H., Fox, K. M., Simon, T., Mehta, S. R., Lev, E. I., Kiss, R. G., Dalby, A. J., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.298 · Cited by 24
Self-citationWang, X., Meng, H., Ruan, J., Chen, W., & Meng, F. (2021) · Medicine · doi:10.1097/md.0000000000023468 · Cited by 19
Metadata
- Authors
- Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., Leonsson-Zachrisson, M., Liu, Y., Opolski, G., Zateyshchikov, D., Ge, J., Nicolau, J. C., Corbalán, R., Cornel, J. H., Widimský, P., & Leiter, L. A.
- Affiliations
- From the French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Université de Paris, INSERM Unité 1148 (P.G.S.), Assistance Publique–Hôpitaux de Paris (P.G.S., T.S.), Hôpital Saint Antoine, Department of Clinical Pharmacology, Unité de Recherche Clinique (T.S.), and Sorbonne Université (T.S.) — all in Paris; the National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London (P.G.S., K.F.); Brigham and Women’s Hospital Heart and...
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Uppsala University (SE)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-03
- Volume
- 381
- Issue
- 14
- Pages
- 1309-1320
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2970797239
- Cited by
- 365
- References
- 32
- Citations by year
- 2026: 27 · 2025: 30 · 2024: 34 · 2023: 48 · 2022: 56 · 2021: 81 · 2020: 75 · 2019: 12
- FWCI
- 40.45
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, stable coronary artery disease, type 2 diabetes, antiplatelet therapy, aspirin, major bleeding, intracranial hemorrhage, cardiovascular events, irreversible harm, treatment discontinuation, P2Y12 inhibitors, elderly patients, cardiovascular risk stratification, bleeding risk assessment, risk-benefit assessment
- MeSH terms
- Ticagrelor, Aged, Aspirin, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Incidence, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.